BioGen AI
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $145M
Overview
An AI-driven biotech using machine learning to design smarter, more targeted drug delivery systems.
OncologyNeurology
Technology Platform
An AI and machine learning platform that models and designs optimized drug delivery systems, including nanoparticles and targeted carriers, to improve therapeutic precision and efficacy.
Funding History
1Total raised:$145M
Series B$145M
Opportunities
Potential to form high-value partnerships with large pharma companies struggling with delivery challenges for complex drug modalities.
Risk Factors
Risk that its in silico delivery predictions fail to translate into effective, manufacturable therapies in animal models and human trials.
Competitive Landscape
Faces competition from both broad AI drug discovery platforms (e.g., Recursion, Exscientia) and specialized drug delivery companies, requiring clear validation of its predictive edge.